145 related articles for article (PubMed ID: 11425271)
1. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
[TBL] [Abstract][Full Text] [Related]
2. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
3. Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.
Silva Soares EW; de Lima Santos SC; Bueno AG; Cavalli IJ; Cavalli LR; Fouto Matias JE; de Souza Fonseca Ribeiro EM
Cancer Genet Cytogenet; 2010 May; 199(1):24-30. PubMed ID: 20417865
[TBL] [Abstract][Full Text] [Related]
4. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
5. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
6. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer.
Sigbjörnsdottir BI; Ragnarsson G; Agnarsson BA; Huiping C; Barkardottir RB; Egilsson V; Ingvarsson S
J Med Genet; 2000 May; 37(5):342-7. PubMed ID: 10807692
[TBL] [Abstract][Full Text] [Related]
8. [Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion].
Tang XL; Yao GY; Chen LR; Yang ZR; Li SL
Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1314-7. PubMed ID: 17217815
[TBL] [Abstract][Full Text] [Related]
9. High frequency of LOH at chromosome 18q in human breast cancer: association with high S-phase fraction and low progesterone receptor content.
Huiping C; Eiriksdottir G; Sigurdsson A; Sigurgeirsdottir JR; Barkardottir RB; Egilsson V; Ingvarsson S
Anticancer Res; 1998; 18(2A):1031-6. PubMed ID: 9615760
[TBL] [Abstract][Full Text] [Related]
10. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite analysis of breast carcinoma and corresponding local recurrences.
Regitnig P; Moser R; Thalhammer M; Luschin-Ebengreuth G; Ploner F; Papadi H; Tsybrovskyy O; Lax SF
J Pathol; 2002 Oct; 198(2):190-7. PubMed ID: 12237878
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients.
Petursdottir TE; Hafsteinsdottir SH; Jonasson JG; Moller PH; Thorsteinsdottir U; Huiping C; Egilsson V; Ingvarsson S
Anticancer Res; 2002; 22(6A):3205-12. PubMed ID: 12530066
[TBL] [Abstract][Full Text] [Related]
13. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
[TBL] [Abstract][Full Text] [Related]
14. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
[TBL] [Abstract][Full Text] [Related]
15. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation.
Ingvarsson S; Geirsdottir EK; Johannesdottir G; Sigbjörnsdóttir BI; Eiriksdottir G; Ragnarsson G; Agnarsson BA; Gudmundsson J; Jonasson JG; Sigurdsson A; Egilsson V; Barkardottir RB
Cancer Res; 1998 Oct; 58(19):4421-5. PubMed ID: 9766673
[TBL] [Abstract][Full Text] [Related]
16. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
[TBL] [Abstract][Full Text] [Related]
17. Loss of Msh2 is not associated with FHIT deletion in breast carcinomas.
Yang Q; Nakamura Y; Nakamura M; Yoshimura G; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
Anticancer Res; 2002; 22(5):2591-5. PubMed ID: 12529969
[TBL] [Abstract][Full Text] [Related]
18. [Allelic loss and down-regulation of FHIT gene expression in esophageal squamous cell carcinoma].
Liu FX; Huang XP; Zhao CX; Xu X; Han YL; Cai Y; Wu RL; Wu M; Zhan QM; Wang MR
Ai Zheng; 2004 Sep; 23(9):992-8. PubMed ID: 15363189
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of loss of heterozygosity in breast cancer].
Iwase H; Iwata H; Toyama T; Hara Y; Omoto Y; Kobayashi S
Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():426-30. PubMed ID: 9589047
[TBL] [Abstract][Full Text] [Related]
20. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]